JP2010509293A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010509293A5 JP2010509293A5 JP2009535750A JP2009535750A JP2010509293A5 JP 2010509293 A5 JP2010509293 A5 JP 2010509293A5 JP 2009535750 A JP2009535750 A JP 2009535750A JP 2009535750 A JP2009535750 A JP 2009535750A JP 2010509293 A5 JP2010509293 A5 JP 2010509293A5
- Authority
- JP
- Japan
- Prior art keywords
- dosage form
- pharmaceutical solid
- solid dosage
- pharmaceutical
- form according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000007909 solid dosage form Substances 0.000 claims 20
- 239000002552 dosage form Substances 0.000 claims 17
- -1 tri-substituted glycerol compound Chemical class 0.000 claims 7
- 238000000034 method Methods 0.000 claims 6
- 239000007787 solid Substances 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 229910019142 PO4 Inorganic materials 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 238000004090 dissolution Methods 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 239000010452 phosphate Substances 0.000 claims 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims 2
- 125000006699 (C1-C3) hydroxyalkyl group Chemical group 0.000 claims 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical group [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- 230000002378 acidificating effect Effects 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 238000013270 controlled release Methods 0.000 claims 1
- 239000007884 disintegrant Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000000945 filler Substances 0.000 claims 1
- 239000007888 film coating Substances 0.000 claims 1
- 238000009501 film coating Methods 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85815706P | 2006-11-10 | 2006-11-10 | |
| US60/858,157 | 2006-11-10 | ||
| PCT/EP2007/062180 WO2008055996A1 (en) | 2006-11-10 | 2007-11-09 | Oral dosage form comprising tri-substituted glycerol compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010509293A JP2010509293A (ja) | 2010-03-25 |
| JP2010509293A5 true JP2010509293A5 (enExample) | 2011-01-06 |
| JP5352466B2 JP5352466B2 (ja) | 2013-11-27 |
Family
ID=39092201
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009535750A Expired - Fee Related JP5352466B2 (ja) | 2006-11-10 | 2007-11-09 | トリ置換グリセロール化合物を含む経口投与剤形、経口投与剤形の調製方法、経口投与剤形の使用方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20110110984A1 (enExample) |
| EP (1) | EP2091520B1 (enExample) |
| JP (1) | JP5352466B2 (enExample) |
| CN (2) | CN103816127A (enExample) |
| AT (1) | ATE546133T1 (enExample) |
| AU (1) | AU2007316588B2 (enExample) |
| CA (1) | CA2668919C (enExample) |
| DK (1) | DK2091520T3 (enExample) |
| ES (1) | ES2382756T3 (enExample) |
| RU (1) | RU2009121838A (enExample) |
| WO (1) | WO2008055996A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1745788A1 (de) * | 2005-07-22 | 2007-01-24 | KTB Tumorforschungsgesellschaft mbH | Acylglycerophospholipide zur Behandlung von Krebs und Tumorkachexie |
| RU2474427C2 (ru) * | 2006-12-20 | 2013-02-10 | Универзитетсклиникум Хамбург-Эппендорф | Применение тризамещенных соединений глицерина для лечения гематологических злокачественных опухолей |
| EP1952803A1 (en) * | 2007-01-23 | 2008-08-06 | KTB-Tumorforschungs GmbH | Solid pharmaceutical dosage form containing hydrogenated phospholipids |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2619686C2 (de) | 1976-05-04 | 1986-08-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen | Verwendung eines Lysolecithins zur Tumorbehandlung |
| DE3530767A1 (de) * | 1985-08-28 | 1987-03-12 | Max Planck Gesellschaft | Mittel gegen multiple sklerose |
| DE3827974A1 (de) * | 1988-08-18 | 1990-02-22 | Boehringer Mannheim Gmbh | Kombinationspraeparate von proteinkinase-c-inhibitoren mit lipiden, lipid-analoga, cytostatica oder inhibitoren von phospholipasen |
| DE3918082A1 (de) * | 1989-06-02 | 1991-01-24 | Max Planck Gesellschaft | Mittel gegen autoimmunerkrankungen |
| DE4000084A1 (de) | 1990-01-03 | 1991-07-04 | Medmark Pharma Gmbh | Intravenoes applizierbare pharmazeutische zubereitung von et18-och(pfeil abwaerts)3(pfeil abwaerts) |
| WO1999030690A1 (en) * | 1997-12-15 | 1999-06-24 | Axia Therapeutics, Inc. | Oral delivery formulation |
| DE19822509A1 (de) * | 1998-05-19 | 1999-11-25 | Medmark Pharma Gmbh | Edelfosin zur Behandlung von Hirntumoren |
| DE19829448A1 (de) | 1998-07-01 | 2000-10-12 | Medmark Pharma Gmbh | 1-Octadecyl-2-methyl-sn-glycero-3-phosphocholin (ET180CH3) zur Behandlung von humanen Mammakarzinomen |
| EP1140112B1 (en) * | 1998-12-21 | 2005-03-09 | Inkeysa, S.A. | Etherlysophospholipids for the treatment of chronic inflammatory diseases |
| BR0307516A (pt) * | 2002-02-01 | 2004-12-07 | Pfizer Prod Inc | Formas de dosagem de liberação imediata contendo dispersões de uma droga sólida |
| US7230012B2 (en) * | 2002-11-14 | 2007-06-12 | Celgene Corporation | Pharmaceutical compositions and dosage forms of thalidomide |
-
2007
- 2007-11-09 AT AT07822468T patent/ATE546133T1/de active
- 2007-11-09 DK DK07822468.0T patent/DK2091520T3/da active
- 2007-11-09 CN CN201310689824.XA patent/CN103816127A/zh active Pending
- 2007-11-09 WO PCT/EP2007/062180 patent/WO2008055996A1/en not_active Ceased
- 2007-11-09 AU AU2007316588A patent/AU2007316588B2/en not_active Ceased
- 2007-11-09 JP JP2009535750A patent/JP5352466B2/ja not_active Expired - Fee Related
- 2007-11-09 EP EP07822468A patent/EP2091520B1/en not_active Not-in-force
- 2007-11-09 CA CA2668919A patent/CA2668919C/en not_active Expired - Fee Related
- 2007-11-09 ES ES07822468T patent/ES2382756T3/es active Active
- 2007-11-09 US US12/514,390 patent/US20110110984A1/en not_active Abandoned
- 2007-11-09 CN CNA2007800417728A patent/CN101610758A/zh active Pending
- 2007-11-09 RU RU2009121838/15A patent/RU2009121838A/ru unknown
-
2017
- 2017-02-22 US US15/439,443 patent/US20170157150A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6162196B2 (ja) | 遅延性持続ドラッグデリバリー | |
| TW576742B (en) | Pharmaceutical composition in solid unit dosage form | |
| JP2016040309A (ja) | パルス状薬剤放出 | |
| JP2016516698A5 (enExample) | ||
| NZ602075A (en) | Abuse-resistant formulations | |
| JP2013512252A5 (enExample) | ||
| JP2010090168A5 (enExample) | ||
| JP5948648B2 (ja) | 安定化されたエペリゾンを含有する徐放性製剤 | |
| RU2015143515A (ru) | Твердые таблетки и капсулы модифицированного высвобождения бензонатата | |
| RU2014115287A (ru) | Фармацевтическая композиция для перорального введения с маскированным вкусом и способ ее получения | |
| HRP20131088T1 (hr) | Äśvrsti farmaceutski pripravci s fiksnom dozom koji sadrže irbesartan i amlodipin, njihova priprava i terapijska primjena | |
| JP2005528430A5 (enExample) | ||
| CN105338970B (zh) | 包含他达拉非和坦洛新的药物胶囊复合制剂 | |
| CN105142617B (zh) | 双用途硫酸盐口服药物组合物片剂及其使用方法 | |
| JP2016503803A5 (enExample) | ||
| JP2011500811A5 (enExample) | ||
| CA2797551A1 (en) | Melt-granulated fingolimod | |
| JP2010509293A5 (enExample) | ||
| KR102055859B1 (ko) | 아캄프로세이트 제제, 그것의 사용 방법, 및 그것을 포함하는 조합 | |
| JP2008534523A5 (enExample) | ||
| JP2015120758A5 (enExample) | ||
| CN102526049A (zh) | 一种复方双氯芬酸钠缓释制剂及其制备方法 | |
| WO2013190151A1 (en) | Pharmaceutical composition comprising fingolimod | |
| RU2009121838A (ru) | Пероральная лекарственая форма, содержащая соединения тризамещенного глицерина | |
| TW200920348A (en) | Combination of picotamide with nafronyl |